# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.85)...
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $45 ...
Craig-Hallum analyst Alex Nowark assumes Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $28.
Goldman Sachs analyst Matthew Sykes maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $32 to...
Guggenheim analyst Subbu Nambi reiterates Guardant Health (NASDAQ:GH) with a Neutral.